Hikma Pharmaceuticals (HKMPY) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Hikma Pharmaceuticals

    PNK: HKMPY · Real-Time Price · USD
    53.81
    -1.74 (-3.13%)
    At close: May 06, 2025, 2:10 PM

    Hikma Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 3.13B 2.88B 2.52B 2.55B
    Cost of Revenue
    		 1.71B 1.47B 1.28B 1.25B
    Gross Profit
    		 1.42B 1.41B 1.24B 1.3B
    Operating Income
    		 612M 367M 507M 582M
    Interest Income
    		 8M 7M 3M 30M
    Pretax Income
    		 455M 281M 233M 544M
    Net Income
    		 359M 190M 188M 421M
    Selling & General & Admin
    		 568M 638M 509M 488M
    Research & Development
    		 141M 149M 144M 143M
    Other Expenses
    		 94M 253M 103M 111M
    Operating Expenses
    		 803M 1.04B 756M 742M
    Interest Expense
    		 88M 87M 70M 69M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 2.52B 2.51B 2.04B 1.99B
    Income Tax Expense
    		 93M 89M 42M 124M
    Shares Outstanding (Basic)
    		 110.67M 55.22M 56M 57.75M
    Shares Outstanding (Diluted)
    		 111.75M 55.59M 56.25M 58.25M
    EPS (Basic)
    		 3.24 3.44 3.36 7.30
    EPS (Diluted)
    		 3.22 3.42 3.34 7.22
    EBITDA
    		 739M 559M 493M 766M
    EBIT
    		 530M 368M 303M 599M
    Depreciation & Amortization
    		 197M 191M 190M 167M

    Add to Watchlist